keyword
MENU ▼
Read by QxMD icon Read
search

leukemia AND treatment

keyword
https://www.readbyqxmd.com/read/30101454/risk-based-management-strategy-and-outcomes-of-tumor-lysis-syndrome-in-children-with-leukemia-lymphoma-analysis-from-a-resource-limited-setting
#1
Kaduveettil Gopinathan Gopakumar, Shwetha Seetharam, Jagathnath Krishna Km, Manjusha Nair, Binitha Rajeswari, Guruprasad Cs, Prasanth Vr, Priyakumari Thankamony
BACKGROUND: Data from low- and middle-income countries on tumor lysis syndrome (TLS) in the pediatric population are limited. This study aims to analyze the clinical and biochemical characteristics and treatment outcomes of TLS in children with leukemia/lymphomas in a resource-limited setting. PROCEDURE: Children with intermediate risk (IRD) and high risk (HRD) for developing TLS were retrospectively studied at a tertiary cancer center in India. RESULTS: Over a three-year period, 224 children with acute leukemia/lymphoma having IRD (21...
August 12, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/30100998/camp-mediated-autophagy-inhibits-dna-damage-induced-death-of-leukemia-cells-independent-of-p53
#2
Seham Skah, Nina Richartz, Eva Duthil, Karin M Gilljam, Christian Bindesbøll, Elin Hallan Naderi, Agnete B Eriksen, Ellen Ruud, Marta M Dirdal, Anne Simonsen, Heidi Kiil Blomhoff
Autophagy is important in regulating the balance between cell death and survival, with the tumor suppressor p53 as one of the key components in this interplay. We have previously utilized an in vitro model of the most common form of childhood cancer, B cell precursor acute lymphoblastic leukemia (BCP-ALL), to show that activation of the cAMP signaling pathway inhibits p53-mediated apoptosis in response to DNA damage in both cell lines and primary leukemic cells. The present study reveals that cAMP-mediated survival of BCP-ALL cells exposed to DNA damaging agents, involves a critical and p53-independent enhancement of autophagy...
July 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/30100518/psychosocial-interventions-for-reduction-of-distress-in-children-with-leukemia-during-bone-marrow-aspiration-and-lumbar-puncture
#3
Hsin-Ju Hsiao, Shih-Hsiang Chen, Tang-Her Jaing, Chao-Ping Yang, Tsung-Yen Chang, Ming-Ying Li, Cheng-Hsun Chiu, Jing-Long Huang
BACKGROUND: Children with cancer undergo many invasive medical procedures that are often painful and highly distressing, including bone marrow aspiration (BMA) and lumbar puncture (LP). Psychosocial interventions have been demonstrated to reduce children's distress resulting from invasive medical procedures. The aim of the study is to assess the efficacy of psychosocial interventions to reduce distress in children with cancer undergoing BMA and LP in a pediatric cancer center in Taiwan...
July 21, 2018: Pediatrics and Neonatology
https://www.readbyqxmd.com/read/30100353/early-achievement-of-full-donor-chimerism-after-allogeneic-hematopoietic-stem-cell-transplantation-predicts-lower-relapse-risk-in-patients-with-acute-lymphoblastic-leukemia
#4
Chien-Ting Chen, Jyh-Pyng Gau, Jing-Hwang Liu, Tzeon-Jye Chiou, Liang-Tsai Hsiao, Yao-Chung Liu
BACKGROUND: Acute lymphoblastic leukemia (ALL) remains one of the most difficult-to-cure hematological malignancies. Allogeneic hematopoietic stem cell transplantation (HSCT) provides curative potential but a substantial proportion of patients eventually will relapse. It is unknown if there are any modifiable factors exists that could improve survival or predict relapse immediately after HSCT is unknown. The aim of this study was to explore whether achieving early (<30 days) full donor chimerism (FDC) could predict disease relapse after allogeneic HSCT in ALL patients...
August 9, 2018: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/30099447/emodin-and-its-combination-with-cytarabine-induce-apoptosis-in-resistant-acute-myeloid-leukemia-cells-in-vitro-and-in-vivo
#5
Yingyu Chen, Donghui Gan, Qinghua Huang, Xiaofeng Luo, Donghong Lin, Jianda Hu
BACKGROUND/AIMS: Acute myeloid leukemia (AML) remains a hematologic malignancy with poor survival and a high risk of relapse, which is mainly caused by the emergence of multidrug resistance (MDR). The identification of novel agents to improve therapeutic strategies becomes important priority for AML treatment. It has been shown that emodin has therapeutic effects on many kinds of human malignant tumors. In this study, we investigated the anti-leukemia effects of emodin alone or in combination with cytarabine (Ara-C) on multidrug-resistant AML HL-60/ADR cells and in a mouse xenograft model of human highly tumorigenic AML HL-60/H3 cells...
August 10, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/30098520/femtosecond-laser-pulse-assisted-photoporation-for-drug-delivery-in-chronic-myelogenous-leukemia-cells
#6
Hemanth Naick Banavath, Srinivasa Rao Allam, Stella Sravanthi Valathati, Alok Sharan, Baskaran Rajasekaran
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder occurs in the pluripotent hematopoietic stem cell. Currently, first-generation tyrosine kinase inhibitor (TKI) imatinib is the mainstay for the treatment of CML. Second generation TKI's like ponatinib, dasatinib, nilotinib, and bafetinib were treated against resistant CML. However, several CML patients develop resistance towards all existing inhibitors. Curcumin (Curcuma longa) a plant-derived natural compound is an effective bioactive component against various cancers including CML...
July 31, 2018: Journal of Photochemistry and Photobiology. B, Biology
https://www.readbyqxmd.com/read/30098484/systematic-reviews-of-economic-burden-and-health-related-quality-of-life-in-patients-with-acute-myeloid-leukemia
#7
REVIEW
Rachel Bosshard, Karl O'Reilly, Stephen Ralston, Shkun Chadda, David Cork
BACKGROUND: Acute myeloid leukemia (AML) is a rare hematologic malignancy largely affecting older adults. Comorbidities may compromise fitness and eligibility for high-intensity chemotherapy (HIC). This study presents the results of two systematic reviews (SRs) assessing (1) the impact of AML and current treatments on health-related quality of life (HRQoL), and (2) the economic burden and cost drivers of AML in patients who are ineligible for HIC. METHODS: Electronic searches (MEDLINE, EMBASE, EconLit, Cochrane library) were supplemented with manual searching of conference, utility, and HTA databases...
July 18, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/30097461/cost-effectiveness-of-ibrutinib-as-first-line-therapy-for-chronic-lymphocytic-leukemia-in-older-adults-without-deletion-17p
#8
James I Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutre, Douglas K Owens, Jeremy D Goldhaber-Fiebert
Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses. Our objective was to evaluate the cost-effectiveness of ibrutinib for first-line treatment of CLL in patients older than age 65 years without a 17p deletion. We developed a semi-Markov model to analyze the cost-effectiveness of ibrutinib vs a comparator therapy from a US Medicare perspective...
August 14, 2018: Blood Advances
https://www.readbyqxmd.com/read/30097433/a-phase-i-iia-trial-using-cd19-targeted-third-generation-car-t-cells-for-lymphoma-and-leukemia
#9
Gunilla Enblad, Hannah Karlsson, Gustav Gammelgard, Jessica Wenthe, Tanja Lovgren, Rose-Marie Amini, Kristina I Wikstrom, Magnus Essand, Barbara Savoldo, Helene Hallbook, Martin Höglund, Gianpietro Dotti, Malcolm K Brenner, Hans Hagberg, Angelica Loskog
PURPOSE: CAR T cell therapy has been effective for patients with CD19+ B cell malignancies. Most studies have investigated second generation CARs with either CD28 or 4-1BB co-stimulatory domains in the CAR receptor. Here we describe the first clinical phase I/IIa trial using third generation CAR T cells targeting CD19 to evaluate safety and efficacy. EXPERIMENTAL DESIGN: Fifteen patients with B cell lymphoma or leukemia were treated with CAR T cells. The lymphoma patients received chemotherapy during CAR manufacture and eleven of fifteen were given low dose cyclophosphamide and fludarabine conditioning prior to CAR infusion...
August 10, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30096576/the-clinical-significance-of-cdx2-in-leukemia-a-new-perspective-for-leukemia-research
#10
REVIEW
Mina Darvishi, Pargol Mashati, Abbas Khosravi
CDX2 gene encodes a transcription factor involved in primary embryogenesis and hematopoietic development; however, the expression of CDX2 in adults is restricted to intestine and is not observed in blood tissues. The ectopic expression of CDX2 has been frequently observed in acute myeloid and lymphoid leukemia which in most cases is concomitant with poor prognosis. Induction of CDX2 in mice leads to hematologic complications, showing the leukemogenic origin of this gene. CDX2 plays significant role in the most critical pathways as the regulator of important transcription factors targeting cell proliferation, multi-drug resistance and survival...
July 29, 2018: Leukemia Research
https://www.readbyqxmd.com/read/30096417/current-time-to-positivity-of-blood-cultures-in-the-febrile-neutropenia-a-tool-to-be-used-in-stewardship-de-escalation-strategies
#11
P Puerta-Alcalde, Cardozo C, M Suárez-Lledó, O Rodríguez-Núñez, L Morata, C Fehér, F Marco, A Del Río, J A Martínez, J Mensa, M Rovira, J Esteve, A Soriano, C Garcia-Vidal
OBJECTIVES: We aimed to describe the current time to positivity (TTP) of blood cultures in onco-hematological patients with febrile neutropenia. We assessed the probability of having multidrug-resistant gram-negative bacilli (MDR-GNB) bloodstream infection (BSI) 24h after cultures were taken, to use this information for antibiotic de-escalation strategies. METHODS: BSI episodes were prospectively collected (2003-2017). When a patient experienced more than one BSI, only one episode was randomly chosen...
August 7, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/30095705/acute-myeloid-leukemia-following-gynecologic-cancer-in-the-era-of-platinum-based-chemotherapy
#12
Dimitrios Nasioudis, Konstantinos Lontos, Anastasia Tsagianni, Michael Boyiadzis, Emily M Ko
OBJECTIVE: The aim of the present study was to estimate the risk of therapy-related acute myeloid leukemia (t-AML) in patients with gynecologic malignancies receiving chemotherapy using a population-based database. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was accessed, and a cohort of women diagnosed with a primary ovarian, uterine, or cervical malignancy between January 1, 1992, and December 31, 2014, who received chemotherapy was selected...
August 7, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/30094928/baseline-characteristics-and-outcomes-of-children-with-cancer-in-the-english-speaking-caribbean-a-multinational-retrospective-cohort
#13
T N Gibson, S Beeput, J Gaspard, C George, D Gibson, N Jackson, V Leandre-Broome, N Palmer-Mitchell, C Alexis, J Bird-Compton, C Bodkyn, R Boyle, S McLean-Salmon, M Reece-Mills, C Sin Quee-Brown, U Allen, S Weitzman, V Blanchette, S Gupta
BACKGROUND: English-speaking Caribbean (ESC) childhood cancer outcomes are unknown. PROCEDURE: Through the SickKids-Caribbean Initiative (SCI), we established a multicenter childhood cancer database across seven centers in six ESC countries. Data managers entered patient demographics, disease, treatment, and outcome data. Data collection commenced in 2013, with retrospective collection to 2011 and subsequent prospective collection. RESULTS: A total of 367 children were diagnosed between 2011 and 2015 with a median age of 5...
August 9, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/30094870/duvelisib-an-oral-dual-pi3k-%C3%AE-%C3%AE-inhibitor-shows-clinical-and-pharmacodynamic-activity-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-in-a-phase-1-study
#14
Susan O'Brien, Manish Patel, Brad S Kahl, Steven M Horwitz, Francine M Foss, Pierluigi Porcu, Jeffrey Jones, Jan Burger, Nitin Jain, Kerstin Allen, Kerrie Faia, Mark Douglas, Howard M Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Ian Flinn
Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-naïve (TN) CLL. Per protocol, TN patients were at least 65 years old or had a del(17p)/TP53 mutation. Duvelisib was administered twice daily (BID) in 28-day cycles at doses of 8-75 mg in RR patients (n=55) and 25 mg in TN patients (n=18...
August 10, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30093506/the-btk-inhibitor-arq-531-targets-ibrutinib-resistant-cll-and-richter-s-transformation
#15
Sean David Reiff, Rose Mantel, Lisa L Smith, Joseph T Greene, Elizabeth M Muhowski, Catherine A Fabian, Virginia M Goettl, Minh Tran, Bonnie Harrington, Kerry A Rogers, Farrukh T Awan, Kami Maddocks, Leslie Andritsos, Amy M Lehman, Deepa Sampath, Rosa Lapalombella, Sudharshan Eathiraj, Giovanni Abbadessa, Brian Schwartz, Amy Johnson, John C Byrd, Jennifer A Woyach
Targeted inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BTK with additional activity against Src family kinases and kinases related to ERK signaling. We hypothesized that targeting additional kinases would improve global inhibition of signaling pathways, producing more robust responses...
August 9, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30093401/gemtuzumab-ozogamicin-in-children-with-relapsed-or-refractory-acute-myeloid-leukemia-a-report-of-berlin-frankfurt-m%C3%A3-nster-study-group
#16
Naghmeh Niktoreh, Beate Lerius, Martin Zimmermann, Bernd Gruhn, Gabriele Escherich, Jean-Pierre Bourquin, Michael Dworzak, Lucie Sramkova, Claudia Rossig, Ursula Creutzig, Dirk Reinhardt, Mareike Rasche
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia have poor survival. We evaluated Gemtuzumab Ozogamicin (CD33-targeted drug) used on compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia-Berlin-Frankfurt-Munster studies and identified 76 patients (<18 years) with highly-advanced and pretreated acute myeloid leukemia [refractory de novo acute myeloid leukemia (n=10), de novo acute myeloid leukemia refractory to relapse (1st early: n=41; 1st late: n=10; 2nd or more: n=10), and secondary acute myeloid leukemia (n=5)]...
August 9, 2018: Haematologica
https://www.readbyqxmd.com/read/30093398/incidence-outcomes-and-risk-factors-of-pleural-effusion-in-patients-receiving-dasatinib-therapy-for-philadelphia-chromosome-positive-leukemia
#17
Timothy P Hughes, Pierre Laneuville, Philippe Rousselot, David S Snyder, Delphine Rea, Neil P Shah, David Paar, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H Lipton, Jorge E Cortes
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. While generally well tolerated, dasatinib has been associated with a higher risk for pleural effusions. Frequency, risk factors, and outcomes associated with pleural effusion were assessed in two phase 3 trials (DASISION and 034/Dose-optimization) and a pooled population of 11 trials that evaluated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib (including DASISION and 034/Dose-optimization)...
August 9, 2018: Haematologica
https://www.readbyqxmd.com/read/30093325/cord-blood-derived-cytokine-induced-killer-cells-combined-with-blinatumomab-as-a-therapeutic-strategy-for-cd19-tumors
#18
Josée Golay, Simona Martinelli, Rachele Alzani, Sabrina Cribioli, Clara Albanese, Elisa Gotti, Bruna Pasini, Benedetta Mazzanti, Riccardo Saccardi, Alessandro Rambaldi, Martino Introna
BACKGROUND: Cytokine-induced killer cells (CIKs) are an advanced therapeutic medicinal product (ATMP) that has shown therapeutic activity in clinical trials but needs optimization. We developed a novel strategy using CIKs from banked cryopreserved cord blood units (CBUs) combined with bispecific antibody (BsAb) blinatumomab to treat CD19+ malignancies. METHODS: CB-CIKs were expanded in vitro and fully characterized in comparison with peripheral blood (PB)-derived CIKs...
August 6, 2018: Cytotherapy
https://www.readbyqxmd.com/read/30093283/improving-outcomes-in-chronic-myeloid-leukemia-over-time-in-the-era-of-tyrosine-kinase-inhibitors
#19
REVIEW
Pradnya Chopade, Luke P Akard
Most patients with chronic myeloid leukemia (CML) receiving treatment with BCR-ABL1 tyrosine kinase inhibitors (TKIs) will achieve favorable responses. Moreover, TKI therapy enables patients to experience long-term survival, with survival rates similar to those of individuals without CML. This enhanced survival has resulted from the availability of multiple BCR-ABL1 TKIs with efficacy, not only in frontline treatment, but, importantly, also in second- and third-line treatment. We have reviewed the changes in long-term outcomes in the era of TKI therapy and how these changes have affected treatment practices...
July 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/30092415/physcion-8-o-%C3%AE-glucopyranoside-exhibits-anti-leukemic-activity-through-targeting-sphingolipid-rheostat
#20
Jinyan Han, Ping Zhao, Weiqin Shao, Zengmin Wang, Fengxue Wang, Lei Sheng
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common fatal cancer in people younger than 20 years of age. This study was designed to explore the anti-leukemia activity of physcion 8-O-β-glucopyranoside (PG) in B-cell ALL. METHODS: NALM6 and SupB15 cells were used as model cell lines. Cell viability, cell apoptosis, cell cycle distribution were determined by CCK-8 assay, DNA fragmentation assay and flow cytometry, and flow cytometry, respectively. Expression of proteins involved in cell apoptosis and cell cycle regulation was determined by western blot and the levels of ceramide and sphingosine 1-phosphate (S1P) were determined by ELISA...
March 16, 2018: Pharmacological Reports: PR
keyword
keyword
165188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"